1. Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern
- Author
-
Bassel Akache, Tyler M. Renner, Matthew Stuible, Nazanin Rohani, Yuneivy Cepero-Donates, Lise Deschatelets, Renu Dudani, Blair A. Harrison, Christian Gervais, Jennifer J. Hill, Usha D. Hemraz, Edmond Lam, Sophie Régnier, Anne E. G. Lenferink, Yves Durocher, and Michael J. McCluskie
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Using our strongly immunogenic SmT1 SARS-CoV-2 spike antigen platform, we developed antigens based on the Beta & Delta variants of concern (VOC). These antigens elicited higher neutralizing antibody activity to the corresponding variant than comparable vaccine formulations based on the original reference strain, while a multivalent vaccine generated cross-neutralizing activity in all three variants. This suggests that while current vaccines may be effective at reducing severe disease to existing VOC, variant-specific antigens, whether in a mono- or multivalent vaccine, may be required to induce optimal immune responses and reduce infection against arising variants.
- Published
- 2022
- Full Text
- View/download PDF